GICS Sector : Healthcare
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69
Nov -16
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
Nov -13
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
Nov -13
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
Nov -10
Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $1,460,000.00 in Stock
Oct -23
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
Oct -20
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
Sep -30
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug -13
LAVA Therapeutics N.V.'s novel bispecific antibodies drive 11.3% growth, fueled by increasing demand for targeted cancer therapies, advancements in antibody engineering, and strategic partnerships. Additionally, expanding pipeline of candidates, growing prevalence of cancer, and rising healthcare expenditure contribute to the segment's rapid expansion.
LAVA Therapeutics N.V. develops gamma-delta T cell engagers, a novel class of bispecific antibodies that selectively target and activate gamma-delta T cells for the treatment of various types of cancer.
LAVA-051 is a gamma-delta T cell engager that targets CD1d, a protein expressed on the surface of certain cancer cells, and activates gamma-delta T cells to kill these cells.
LAVA-1207 is a gamma-delta T cell engager that targets a tumor-specific antigen and activates gamma-delta T cells to kill cancer cells.
LAVA Therapeutics N.V. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
LAVA Therapeutics N.V. has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.
LAVA Therapeutics N.V. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power, but the company's strong relationships with suppliers mitigate this threat.
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to LAVA Therapeutics N.V.'s market share.
The biotechnology industry is highly competitive, and LAVA Therapeutics N.V. faces intense rivalry from established companies and new entrants, making it challenging to maintain market share.
| Value | |
|---|---|
| Debt Weight | 10.98% |
| Debt Cost | 3.95% |
| Equity Weight | 89.02% |
| Equity Cost | 7.35% |
| WACC | 6.97% |
| Leverage | 12.34% |
Value: 6.4
Growth: 6.6
Quality: 4.1
Yield: 0.0
Momentum: 7.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.0
Growth: 2.9
Quality: 5.0
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 1.1
Growth: 4.4
Quality: 7.8
Yield: 1.2
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.8
Growth: 5.6
Quality: 3.0
Yield: 0.0
Momentum: 3.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.2
Growth: 4.0
Quality: 4.3
Yield: 0.0
Momentum: 4.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.0
Growth: 4.2
Quality: 3.8
Yield: 0.0
Momentum: 4.0
Volatility: 0.0
1-Year Total Return ->